A C Moss

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Adding fuel to the fire: GM-CSF for active Crohn's disease
    Alan C Moss
    Gastroenterology 129:2115-7. 2005
  2. ncbi request reprint Combined oral and topical mesalazine treatment for extensive ulcerative colitis
    Alan C Moss
    Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Nat Clin Pract Gastroenterol Hepatol 3:290-3. 2006
  3. ncbi request reprint Reducing the torment of diarrhea: tormentil for active ulcerative colitis
    Alan C Moss
    J Clin Gastroenterol 41:797-8. 2007
  4. doi request reprint The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease
    A C Moss
    Harvard Medical School, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Aliment Pharmacol Ther 28:221-7. 2008
  5. ncbi request reprint Steroid-refractory severe ulcerative colitis: what are the available treatment options?
    Alan C Moss
    Harvard Medical School, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Drugs 68:1157-67. 2008
  6. ncbi request reprint Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis
    Jennifer Devlen
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 022156, USA
    J Manag Care Pharm 20:309-14. 2014
  7. doi request reprint Prevention of postoperative recurrence of Crohn's disease: what does the evidence support?
    Alan C Moss
    Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Inflamm Bowel Dis 19:856-9. 2013
  8. pmc In silico gene expression analysis--an overview
    David Murray
    General Clinical Research Unit, UCD School of Medicine and Medical Sciences, Mater Misericordiae University Hospital, Dublin 7, Ireland
    Mol Cancer 6:50. 2007
  9. doi request reprint Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab
    Alan C Moss
    Harvard Medical School, Beth Israel Deaconess Medical Center, Center for Inflammatory Bowel Disease, Rabb 4 East, BIDMC, 330 Brookline Ave, Boston, MA 02215, USA
    Dig Dis Sci 55:1413-20. 2010
  10. ncbi request reprint Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results
    Alan C Moss
    Gastrointestinal Unit, Mater Misericordiae University Hospital, Eccles Street, Dublin 1, Ireland
    Cancer Treat Rev 33:213-21. 2007

Collaborators

Detail Information

Publications32

  1. ncbi request reprint Adding fuel to the fire: GM-CSF for active Crohn's disease
    Alan C Moss
    Gastroenterology 129:2115-7. 2005
  2. ncbi request reprint Combined oral and topical mesalazine treatment for extensive ulcerative colitis
    Alan C Moss
    Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Nat Clin Pract Gastroenterol Hepatol 3:290-3. 2006
    ..6 g/day. The severity of symptoms had affected her plans to have children...
  3. ncbi request reprint Reducing the torment of diarrhea: tormentil for active ulcerative colitis
    Alan C Moss
    J Clin Gastroenterol 41:797-8. 2007
  4. doi request reprint The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease
    A C Moss
    Harvard Medical School, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Aliment Pharmacol Ther 28:221-7. 2008
    ..Little is known about long-term outcomes in patients who experience infusion reactions while receiving infliximab...
  5. ncbi request reprint Steroid-refractory severe ulcerative colitis: what are the available treatment options?
    Alan C Moss
    Harvard Medical School, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Drugs 68:1157-67. 2008
    ..Key issues remain as to what should be first- and second-line therapies, when surgery should be undertaken, and the risk of switching between immunosuppressants in these critical patients...
  6. ncbi request reprint Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis
    Jennifer Devlen
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 022156, USA
    J Manag Care Pharm 20:309-14. 2014
    ..The causes for nonadherence to mesalamine in patients with inflammatory bowel disease (IBD) have been characterized using mostly indirect methods. Patient-reported barriers are lacking in this population...
  7. doi request reprint Prevention of postoperative recurrence of Crohn's disease: what does the evidence support?
    Alan C Moss
    Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Inflamm Bowel Dis 19:856-9. 2013
    ..Ongoing trials using this "tailored" strategy should provide answers on whether this approach allows optimal selection of proven therapies...
  8. pmc In silico gene expression analysis--an overview
    David Murray
    General Clinical Research Unit, UCD School of Medicine and Medical Sciences, Mater Misericordiae University Hospital, Dublin 7, Ireland
    Mol Cancer 6:50. 2007
    ....
  9. doi request reprint Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab
    Alan C Moss
    Harvard Medical School, Beth Israel Deaconess Medical Center, Center for Inflammatory Bowel Disease, Rabb 4 East, BIDMC, 330 Brookline Ave, Boston, MA 02215, USA
    Dig Dis Sci 55:1413-20. 2010
    ..4, 95% CI 0.1-1.5, P = 0.1). The combination of maintenance infliximab and an immunomodulator produced modest improvements in outcomes beyond maintenance infliximab alone in this cohort...
  10. ncbi request reprint Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results
    Alan C Moss
    Gastrointestinal Unit, Mater Misericordiae University Hospital, Eccles Street, Dublin 1, Ireland
    Cancer Treat Rev 33:213-21. 2007
    ..Surgical bypass and endoscopic stents are available for palliative bypass of malignant distal biliary obstruction...
  11. doi request reprint Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study
    Alan C Moss
    Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Rose 1 East, BIDMC, 330 Brookline Ave, Boston, MA 02215, United States
    J Crohns Colitis 4:171-5. 2010
    ..We sought to determine whether a nurse-delivered patient-support program could improve medication adherence in these patients...
  12. ncbi request reprint ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion
    Alan C Moss
    Conway Institute of Biomolecular and Biomedical Research, UCD, Ireland
    Biochem Biophys Res Commun 345:216-21. 2006
    ..Myeov knockdown resulted in a 48% decrease in cell proliferation (p<0.05) and a 36% decrease in cell invasion. These data suggest that ETV4 and Myeov may provide novel targets for therapeutic intervention...
  13. pmc Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease
    A Abhyankar
    Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Aliment Pharmacol Ther 38:460-6. 2013
    ..The rate of exacerbation of inflammatory bowel disease (IBD) during pregnancy varies in the published literature...
  14. doi request reprint Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease
    G A Doherty
    Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 31:802-9. 2010
    ..Enteric bacteria play an important early role in the pathogenesis of Crohn's disease...
  15. doi request reprint The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome
    C Lahiff
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 37:786-94. 2013
    ....
  16. pmc Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis
    E Rostholder
    Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Aliment Pharmacol Ther 35:562-7. 2012
    ..Infliximab (IFX) therapy escalation during maintenance treatment occurs frequently in clinical practice in patients with ulcerative colitis (UC). Outcomes for these patients have not been described...
  17. doi request reprint Cyclosporine is safe and effective in patients with severe ulcerative colitis
    Adam S Cheifetz
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Gastroenterol 45:107-12. 2011
    ..The aim of this study was to assess the long-term colectomy-sparing effects and safety of CSA in patients hospitalized for ulcerative colitis...
  18. doi request reprint Balsalazide disodium for the treatment of ulcerative colitis
    Seema A Patil
    Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Expert Rev Gastroenterol Hepatol 2:177-84. 2008
    ..The introduction of novel aminosalicylate formulations and an appreciation of their molecular mode of action, has renewed interest in these agents in both maintenance of disease remission and cancer prevention...
  19. ncbi request reprint Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab
    A C Moss
    Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Gastroenterology 132:488, 829. 2007
  20. ncbi request reprint Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes
    Nielsen Q Fernandez-Becker
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Drugs 68:1089-103. 2008
    ..The development of delivery methods that allow once-daily administration represents a potential means to improve the low medication adherence rates reported in patients with ulcerative colitis...
  21. doi request reprint Once-daily mesalamine granules for ulcerative colitis
    Garrett Lawlor
    Harvard Medical School, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Expert Rev Clin Immunol 6:521-6. 2010
    ..This article examines the efficacy and safety of mesalamine extended-release capsules in the maintenance of remission in patients with UC...
  22. doi request reprint The utility of capsule endoscopy in patients with suspected Crohn's disease
    Melissa Tukey
    Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Gastroenterol 104:2734-9. 2009
    ..We sought to determine the utility of CE for the subsequent diagnosis of CD in patients suspected to have this condition...
  23. doi request reprint The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis
    J L Pleet
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Aliment Pharmacol Ther 39:940-8. 2014
    ..Hospitalised patients with inflammatory bowel disease are 1.5- to 3.5-fold more likely to develop venous thromboembolism compared to controls. Clinical guidelines recommend pharmacological prophylaxis...
  24. ncbi request reprint Clinical results of CT colonoscopy
    J F Bruzzi
    Departments of Radiology and Gastroenterology, Mater Misericordiae Hospital, Eccles Street, Dublin 7, Ireland
    Eur Radiol 11:2188-94. 2001
    ..This review summarises the development of CT colonography to date, evaluates its applications and performance in the detection and screening of colorectal polyps and looks at future directions of this exciting technique...
  25. pmc Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha
    Alan C Moss
    Gastrointestinal Neuropeptide Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Gut 56:1210-7. 2007
    ..UcnII is synthesised in the intestine, but its role in human intestinal inflammation is largely unknown...
  26. ncbi request reprint The risks and the benefits of mesalazine as a treatment for ulcerative colitis
    Alan C Moss
    Inflammatory Bowel Disease Fellow, Harvard Medical School, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Expert Opin Drug Saf 6:99-107. 2007
    ..In particular, worsening of colitis, interstitial pneumonitis and nephritis are of concern to clinicians. Fortunately these reactions are mostly reversible with cessation of therapy...
  27. ncbi request reprint Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction
    Alan C Moss
    Gastrointestinal Unit, Mater Misericordiae University Hospital, Dublin, Ireland
    Eur J Gastroenterol Hepatol 19:1119-24. 2007
    ..Although metal stents are associated with longer patency, their costs are significantly higher than plastic stents...
  28. ncbi request reprint Efficacy of IV Buscopan as a muscle relaxant in CT colonography
    John F Bruzzi
    Department of Radiology, Mater Misericordiae Hospital, Eccles Street, Dublin 7, Ireland
    Eur Radiol 13:2264-70. 2003
    ..In patients with sigmoid diverticular disease IV Buscopan improves distension of more proximal colonic segments and may be useful in selected cases, but our results do not support its routine use for CT colonography...
  29. ncbi request reprint Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses
    Efi Kokkotou
    Gastrointestinal Neuropeptide Center, Gastroenterology Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunol 177:3355-61. 2006
    ..Taken together, these results provide direct evidence that CRHR2 mediates intestinal inflammatory responses via release of proinflammatory mediators at the colonocyte level...
  30. ncbi request reprint Curcumin for maintenance therapy in ulcerative colitis
    Alan C Moss
    Clin Gastroenterol Hepatol 5:642; author reply 642. 2007
  31. ncbi request reprint Thyroid cancer and Crohn's disease: association or coincidence?
    Alan C Moss
    Inflamm Bowel Dis 12:79-80. 2006
  32. ncbi request reprint Infliximab for induction and maintenance therapy for ulcerative colitis
    Alan C Moss
    Gastroenterology 131:1649-51; discussion 1651. 2006